Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826901 · ClinicalTrials.gov registry record · Phase 1
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT03826901 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 46 participants.
The verdict
NCT03826901, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
Interventions
- DRUG delgocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2021-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03826901
The ClinicalTrials.gov registry entry for NCT03826901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which delgocitinib is the first listed.
NCT03826901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03826901 about?
NCT03826901 is a clinical study titled "Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children". This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
What is the current status of trial NCT03826901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2019-02-20. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT03826901?
The interventions under investigation include: delgocitinib (DRUG).
Who is sponsoring clinical trial NCT03826901?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.